Dexcom has announced that Health Canada has approved its next-generation Dexcom G7 continuous glucose monitoring (CGM) system for all types of diabetes patients of age two years and older.
The US-based medical technology company has designed the CGM system to control and manage diabetes. The device is said to be 60% smaller than the company’s Dexcom G6 version.
Dexcom G7 allows users to monitor real-time glucose readings relayed automatically to their compatible smart device or receiver, without the requirement of scanning or pricking their finger on a regular basis.
Its low-profile, all-in-one sensor and transmitter warm up two times quicker than any other CGM on the market for a quick, simple start, the CGM systems maker said.
Dexcom G7 has a range of programmable alerts that can assist users to stay in range longer by warning of high or low glucose levels with a predictive urgent low alert to prevent dangerous hypoglycaemia situations.
According to Dexcom, users may also share information with family, friends, and care teams wherever they are, at any time, through remote monitoring and reporting features.
Dexcom Canada vice president and general manager André Côté said: “With our latest advancements in sensor technology and software integrations, we’re entering a new era of diabetes care with continuous glucose monitoring at the centre. Dexcom G7 builds on the innovation that our previous CGM systems have brought to the lives of Canadians.
“With greater accuracy, a simplified user experience, proven results and extensive digital connectivity, our next-generation Dexcom G7 will support greater quality of life and improved outcomes for people with diabetes, and we couldn’t be more excited to bring it to Canada by the end of 2023.”
Furthermore, the CGM maker claimed that Dexcom G7 has been shown to bring down hospitalisations and emergency room visits due to hypoglycemia by up to 42%.
Some of the other features of the device include a redesigned and simplified mobile application integrated with the Dexcom Clarity software. It also has a 12-hour grace period to change finished sensors for a smooth transition between sessions.
Last year in December, the US Food and Drug Administration (FDA) cleared Dexcom G7 for people with all types of diabetes in the US.
